Paratek Pharmaceuticals, Inc., has announced that the US Food and Drug Administration (FDA) has approved Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥9 years. Paratek Pharmaceuticals is headquartered in Boston, MA.
Dosage/administration: The recommended dosage of Seysara is once daily with or without food and is based on the patient’s weight:
• 60 mg for patients who weigh 33-54 kg,
• 100 mg for patients who weigh 55-84 kg,
• 150 mg for patients who weigh 85-136 kg.
Adverse effects: The most common adverse reaction (incidence ≥ 1%) is nausea.
FDA approves Seysara (sarecycline) for the treatment of moderate to severe acne. [news release]. Boston, MA: Paratek Pharmaceuticals, Inc. October 2, 2018. https://www.biospace.com/article/releases/fda-approves-seysara-sarecycline-for-the-treatment-of-moderate-to-severe-acne/. Accessed October 18, 2018.
This Week's Must Reads
Link Found Between AD, Depression, Suicidal Ideation , J Am Acad Dermatol; 2019 Feb; Patel, et al
Patients with Persistent Post-Chemotherapy Alopecia, JAMA Dermatol; ePub 2019 Mar 6; Freites-Martinez, et al
Risk Prediction of In-Hospital Mortality for SJS/TEN, JAMA Dermatol; ePub 2019 Mar 6; Noe, et al
Melanoma Rates Before and After AJCC 7 Enactment, JAMA Dermatol; ePub 2019 Mar 6; Isom, et al
Must Reads in Acne
FDA Approves Seysara for Severe Acne Vulgaris, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2
Prevalence of Acne Vulgaris Among Patients with HS, J Am Acad Dermatol; ePub 2018 Oct 1; Wertenteil, et al
Acne Successfully Treated with Laser Combination, Dermatolog Surg; ePub 2018 Jun 5; Bakus, et al
Large Acne Study of Twins Supports Genetic Link, J Drugs Dermatol; 2018 Apr 1; Suggs, Loesch, et al
Hormonal Antiandrogen Acne Treatment Examined, Am J Clin Dermatol; ePub 2018 Mar 20; Park, et al